Trial Profile
Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation into Tumour GENe status and Correlation with Efficacy – 1st Exploratory Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms DILIGENCE-1
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Sub-analysis presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 01 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 Jun 2015.